Cargando…
Activatable molecular agents for cancer theranostics
Theranostics that integrates diagnosis and treatment modalities has attracted great attention due to its abilities of personalized therapy and real-time monitoring of therapeutic outcome. Such a theranostic paradigm requires agents to simultaneously possess the capabilities of targeting, imaging, an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145638/ https://www.ncbi.nlm.nih.gov/pubmed/34123034 http://dx.doi.org/10.1039/c9sc05460j |
_version_ | 1783697221313626112 |
---|---|
author | Zhang, Jianjian Ning, Lulu Huang, Jiaguo Zhang, Chi Pu, Kanyi |
author_facet | Zhang, Jianjian Ning, Lulu Huang, Jiaguo Zhang, Chi Pu, Kanyi |
author_sort | Zhang, Jianjian |
collection | PubMed |
description | Theranostics that integrates diagnosis and treatment modalities has attracted great attention due to its abilities of personalized therapy and real-time monitoring of therapeutic outcome. Such a theranostic paradigm requires agents to simultaneously possess the capabilities of targeting, imaging, and treatment. Activatable molecular agents (AMAs) are promising for cancer theranostics, as they show a higher signal-to-noise ratio (SNR), real-time detection of cancer-associated biomarkers, lower normal tissue toxicity, and a higher therapeutic effect. This perspective summarizes the recent advancements of AMAs, which include imaging-guided chemotherapy, imaging-guided photodynamic therapy, and imaging-guided photothermal therapy. The molecular design principles, theranostic mechanisms, and biomedical applications of AMAs are described, followed by a discussion of potential challenges of AMAs in cancer theranostics. |
format | Online Article Text |
id | pubmed-8145638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-81456382021-06-11 Activatable molecular agents for cancer theranostics Zhang, Jianjian Ning, Lulu Huang, Jiaguo Zhang, Chi Pu, Kanyi Chem Sci Chemistry Theranostics that integrates diagnosis and treatment modalities has attracted great attention due to its abilities of personalized therapy and real-time monitoring of therapeutic outcome. Such a theranostic paradigm requires agents to simultaneously possess the capabilities of targeting, imaging, and treatment. Activatable molecular agents (AMAs) are promising for cancer theranostics, as they show a higher signal-to-noise ratio (SNR), real-time detection of cancer-associated biomarkers, lower normal tissue toxicity, and a higher therapeutic effect. This perspective summarizes the recent advancements of AMAs, which include imaging-guided chemotherapy, imaging-guided photodynamic therapy, and imaging-guided photothermal therapy. The molecular design principles, theranostic mechanisms, and biomedical applications of AMAs are described, followed by a discussion of potential challenges of AMAs in cancer theranostics. The Royal Society of Chemistry 2019-11-22 /pmc/articles/PMC8145638/ /pubmed/34123034 http://dx.doi.org/10.1039/c9sc05460j Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Zhang, Jianjian Ning, Lulu Huang, Jiaguo Zhang, Chi Pu, Kanyi Activatable molecular agents for cancer theranostics |
title | Activatable molecular agents for cancer theranostics |
title_full | Activatable molecular agents for cancer theranostics |
title_fullStr | Activatable molecular agents for cancer theranostics |
title_full_unstemmed | Activatable molecular agents for cancer theranostics |
title_short | Activatable molecular agents for cancer theranostics |
title_sort | activatable molecular agents for cancer theranostics |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145638/ https://www.ncbi.nlm.nih.gov/pubmed/34123034 http://dx.doi.org/10.1039/c9sc05460j |
work_keys_str_mv | AT zhangjianjian activatablemolecularagentsforcancertheranostics AT ninglulu activatablemolecularagentsforcancertheranostics AT huangjiaguo activatablemolecularagentsforcancertheranostics AT zhangchi activatablemolecularagentsforcancertheranostics AT pukanyi activatablemolecularagentsforcancertheranostics |